# Safety and Efficacy of Express LD to Treat Stenosed or Occlusive Atherosclerotic Disease in Iliac Arteries

> **NCT00352222** · PHASE3 · COMPLETED · sponsor: **Boston Scientific Corporation** · enrollment: 150 (—)

## Conditions studied

- Arterial Occlusive Disease
- Intermittent Claudication
- Atherosclerotic Disease
- Thrombosis

## Interventions

- **DEVICE:** stent implantation

## Key facts

- **NCT ID:** NCT00352222
- **Lead sponsor:** Boston Scientific Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-01
- **Primary completion:** 2005-07
- **Final completion:** 2007-02
- **Target enrollment:** 150 (—)
- **Last updated:** 2008-09-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00352222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00352222, "Safety and Efficacy of Express LD to Treat Stenosed or Occlusive Atherosclerotic Disease in Iliac Arteries". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00352222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*